Published On: 21 Nov, 2021 10:26 PM | Updated On: 21 Dec, 2024 9:13 PM
Should DCGI (Drug Controller General of India) take back febuxostat drug from the market?
Dr. K K Aggarwal, President Heart Care Foundation of India and Group Editor in Chief MEDtalks, will talk on the topic whether DCGI (Drug Controller General of India) should withdraw febuxostat from the market in this video. Febuxostat is given to reduce uric acid in the body. It is often misused drug in our country. If the uric acid levels are more than 10 and patient is asymptomatic then no need to treat them. High uric acid is the indicator of metabolic syndrome. It is been rejected twice by USFDA stating that it causes cardiovascular complications.
More FAQs by
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article